Abstract 124P
Background
FGFR2 gene F/R is present in 10-15% of iCCA and FGFR2 inhibitors have demonstrated significant antitumor activity in this population. However, specific clinicopathological features of iCCA patients (pts) harboring FGFR 2 gene F/R have not yet been well clarified. So far, limited literature data seem suggest a correlation between FGFR2 gene F/R and young age and female gender. The aim of this study is to construct a nomogram predicting FGFR2 gene status.
Methods
iCCA pts from four Italian Institutions were retrospectively collected. The following clinicopathological variables were selected: gender; age (< 55 vs ≥ 55 years); synchronous vs metachronous metastases (mts); number of metastatic sites (1 vs >1), lung/distant lymph-node/peritoneal/bone mts (present vs absent). A multivariate logistic regression model was used to screen out independent predictive factors with a cut-off of 0.10 and a nomogram was established.
Results
Among 464 iCCA pts retrospectively evaluated, 63 (14%) had FGFR2 gene F/R. Univariate and multivariate analysis suggested that age < 55 years [odds ratio (OR): 2.06, 95% confidence interval (CI) 1.15-3.9], bone mts (OR: 2.58, 95% CI 1.28-5.20) and female gender (OR: 1.53, 95% CI 0.88–2.67) were independent predictive factors of FGFR2 gene F/R. A predictive nomogram was established: pts with the highest score (age < 55 years, bone mts, female gender) had a 60% chance to bear FGFR2 gene F/R iCCA [AUC 0.64 (95% CI: 0.57 -0.72)] in comparison to pts with low score (age ≥ 55 years, no bone mts, male gender) which had a 7% chance to have FGFR2 positive iCCA.
Conclusions
In the era of molecular characterization, we have developed a simple nomogram for predicting FGFR2 gene status in iCCA. This nomogram might help clinicians to identify pts more likely to harbour FGFR2 gene F/R and increase their therapeutic opportunities. An external validation-set will be analyzed to improve predictive performance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Gemelli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Presenter: Changhoon Yoo
Session: Poster session 17
101P - Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Presenter: Harpreet Wasan
Session: Poster session 17
102P - Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster session 17
103P - Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
Presenter: Jaewon Hyung
Session: Poster session 17
104P - Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Presenter: Hyehyun Jeong
Session: Poster session 17
105P - A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy
Presenter: Jia Fan
Session: Poster session 17